Carmen Miano Selected Research

Breast Neoplasms (Breast Cancer)

3/2022	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.
1/2022	Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carmen Miano Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 03/2022 - 01/2022
2	Neoplasms (Cancer) 03/2022 - 01/2022
1	Colonic Neoplasms (Colon Cancer) 03/2022
1	Triple Negative Breast Neoplasms 03/2022
1	Cardiotoxicity 01/2022
1	Heart Failure 01/2022
1	Fibrosis (Cirrhosis) 11/2019

Drug/Important Bio-Agent (IBA)

2	LigandsIBA 03/2022 - 01/2022
2	Messenger RNA (mRNA)IBA 03/2022 - 01/2022
1	Neuregulin-1 (Neuregulin 1)IBA 03/2022
1	Neutralizing AntibodiesIBA 03/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	SuspensionsIBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	NeuregulinsIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	Insulin-Like Growth Factor I (IGF-1)IBA 11/2019
1	Interleukin-6 (Interleukin 6)IBA 11/2019

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2022
1	Therapeutics 01/2022